The incidence and clinical significance of amiodarone and acenocoumarol interaction.
Acenocoumarol sensitivity index (ASI) was calculated in 36 patients receiving amiodarone and acenocoumarol concomitantly, by dividing the acenocoumarol daily dose (micrograms kg-1 day-1) by the prothrombin ratio expressed as International Normalised Ratio (INR). It was found to be significantly lower (4.2 +/- 0.3 micrograms kg-1 day-1) than the ASI (11 +/- 0.6 micrograms kg-1 day-1) determined in 35 patients in the control group, who received acenocoumarol and not amiodarone. In 15 patients, ASI was 13.2 +/- 1.4 and 4.2 +/- 0.6 micrograms kg-1 day-1 before and after initiation of amiodarone therapy, respectively. In 5 patients, ASI was 6.2 +/- 0.6 micrograms kg-1 day-1, while patients were receiving both medications, and 28.1 +/- 6.1 micrograms kg-1 day-1 following discontinuation of amiodarone therapy. ASI determined while patients were on both medications was not affected by the presence of mild impaired renal or liver function. In 7 patients treated with both drugs concomitantly, severe bleeding diathesis developed. It is concluded that amiodarone augmented the anticoagulant effect of acenocoumarol in all patients receiving both drugs. An initial reduction of acenocoumarol daily dose by 50% and further adjustment of acenocoumarol dose according to daily prothrombin ratio is recommended. It is also suggested that acenocoumarol dose should be adjusted after cessation of amiodarone therapy.
Caraco
Y
Y
Department of Medicine B, Hadassah University Hospital, Jerusalem, Israel.
Chajek-Shaul
T
T
D000074:Acenocoumarol / Q000494:pharmacology*; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged
D000074:Acenocoumarol; D000638:Amiodarone